Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments

References

• Berry AM, Paton JC. (1996). Sequence heterogeneity of PsaA, a 37-kilodalton putative adhesin essential for virulence of Streptococcus pneumoniae. Infect Immun, 64, 5255–62
   PubMed Web of Science ®Google Scholar
• Black SB, Shinefield HR, Ling S, et al. (2002). Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J, 21, 810–15
   PubMed Web of Science ®Google Scholar
• Briles DE, Ades E, Paton JC, et al. (2000a). Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect Immun, 68, 796–800
   PubMed Web of Science ®Google Scholar
• Briles DE, Hollingshead SK, King J, et al. (2000b). Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis, 182, 1694–701
   PubMed Web of Science ®Google Scholar
• Briles DE, Hollingshead SK, Nabors GS. (2000c). The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae. Vaccine, 19, S87–95
   PubMed Web of Science ®Google Scholar
• Briles DE, Hollingshead SK, Paton JC, et al. (2003). Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. J infect Dis, 188, 339–48
   PubMed Web of Science ®Google Scholar
• Briles DE, Tart RC, Swiatlo E, et al. (1998). Pneumococcal diversity: Considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA). Clin Microbiol Rev, 11, 645–57
   PubMed Web of Science ®Google Scholar
• Briles DE, Tart RC, Wu HY, et al. (1996). Systemic and mucosal protective immunity to pneumococcal surface protein A. Ann NY Acad Sci, 797, 118–26
   PubMedGoogle Scholar
• Croney CM, Coats MT, Nahm MH, et al. (2012). PspA family distribution, unlike capsular serotype, remains unaltered following introduction of the heptavalent pneumococcal conjugate vaccine. Clin Vaccine Immunol, 19, 891–6
   PubMedGoogle Scholar
• Croney CM, Nahm MH, Juhn SK, et al. (2013). Invasive and noninvasive Streptococcus pneumoniae capsule and surface protein diversity following the use of a conjugate vaccine. Clin Vaccine Immunol, 20, 1711–18
   Google Scholar
• Cutts FT, Zaman SMA, Enwere G, et al. (2005). Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: Randomised, double-blind, placebo-controlled trial. Lancet, 365, 1139–46
   PubMed Web of Science ®Google Scholar
• Dagan R, Kayhty H, Wuorimaa T, et al. (2004). Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants. Pediatr Infect Dis J, 23, 91–8
   PubMed Web of Science ®Google Scholar
• Daniels CC, Briles TC, Mirza S, et al. (2006). Capsule does not block antibody binding to PspA, a surface virulence protein of Streptococcus pneumoniae. Microb Pathog, 40, 228–33
   PubMedGoogle Scholar
• Darrieux M, Goulart C, Briles D, Leite LC. (2015). Current status and perspectives on protein-based pneumococcal vaccines. Crit Rev Microbiol, 41, 190--200
   PubMed Web of Science ®Google Scholar
• Darrieux M, Miyaji EN, Ferreira DM, et al. (2007). Fusion proteins containing family 1 and family 2 PspA fragments elicit protection against Streptococcus pneumoniae that correlates with antibody-mediated enhancement of complement deposition. Infect Immun, 75, 5930–8
   PubMed Web of Science ®Google Scholar
• Dintilhac A, Alloing G, Granadel C, Claverys JP. (1997). Competence and virulence of Streptococcus pneumoniae: Adc and PsaA mutants exhibit a requirement for Zn and Mn resulting from inactivation of putative ABC metal permeases. Mol Microbiol, 25, 727–39
   PubMed Web of Science ®Google Scholar
• Ferreira DM, Oliveira ML, Moreno AT, et al. (2010). Protection against nasal colonization with Streptococcus pneumoniae by parenteral immunization with a DNA vaccine encoding PspA (pneumococcal surface protein A). Microb Pathog, 48, 205–13
   PubMed Web of Science ®Google Scholar
• Goulart C, da Silva TR, Rodriguez D, et al. (2013). Characterization of protective immune responses induced by pneumococcal surface protein A in fusion with pneumolysin derivatives. PLoS One, 8, e59605
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Feikin DR, Klugman KP. (2005). Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis, 5, 83–93
   PubMed Web of Science ®Google Scholar
• Hollingshead SK, Becker R, Briles DE. (2000). Diversity of PspA: Mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun, 68, 5889–900
   PubMed Web of Science ®Google Scholar
• Kadkhodazadeh M, Baghani Z, Ebadian AR, et al. (2013). IL-17 gene polymorphism is associated with chronic periodontitis and peri-implantitis in Iranian patients: A cross-sectional study. Immunol Investig, 42, 156–63
   PubMed Web of Science ®Google Scholar
• Lu YJ, Forte S, Thompson CM, et al. (2009). Protection against Pneumococcal colonization and fatal pneumonia by a trivalent conjugate of a fusion protein with the cell wall polysaccharide. Infect Immun, 77, 2076–83
   Google Scholar
• Lu YJ, Gross J, Bogaert D, et al. (2008). Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog, 4, e1000159
   PubMed Web of Science ®Google Scholar
• Lu J, Sun T, Hou H, et al. (2014). Detoxified pneumolysin derivative Plym2 directly protects against pneumococcal infection via induction of inflammatory cytokines. Immunol Investig, 43, 717–26
   PubMed Web of Science ®Google Scholar
• McAllister LJ, Tseng HJ, Ogunniyi AD, et al. (2004). Molecular analysis of the PSA permease complex of Streptococcus pneumoniae. Mol Microbiol, 53, 889–901
   PubMed Web of Science ®Google Scholar
• Moffitt KL, Malley R. (2011). Next generation pneumococcal vaccines. Curr Opin Immunol, 23, 407–13
   PubMed Web of Science ®Google Scholar
• Moreno AT, Oliveira ML, Ferreira DM, et al. (2010). Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection. Clin Vaccine Immunol, 17, 439–46
   PubMedGoogle Scholar
• Nabors GS, Braun PA, Herrmann DJ, et al. (2000). Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine, 18, 1743–54
   PubMed Web of Science ®Google Scholar
• Nguyen CT, Kim SY, Kim MS, et al. (2011). Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice. Vaccine, 29, 5731–9
   PubMed Web of Science ®Google Scholar
• Novak R, Braun JS, Charpentier E, Tuomanen E. (1998). Penicillin tolerance genes of Streptococcus pneumoniae: The ABC-type manganese permease complex Psa. Mol Microbiol, 29, 1285–96
   PubMedGoogle Scholar
• O'Brien KL, Wolfson LJ, Watt JP, et al. (2009). Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: Global estimates. Lancet, 374, 893–902
   PubMed Web of Science ®Google Scholar
• Rajam G, Anderton JM, Carlone GM, et al. (2008). Pneumococcal surface adhesin A (PsaA): A review. Crit Rev Microbiol, 34, 131–42
   PubMed Web of Science ®Google Scholar
• Ren B, Li J, Genschmer K, et al. (2012). The absence of PspA or presence of antibody to PspA facilitates the complement-dependent phagocytosis of pneumococci in vitro. Clin Vaccine Immunol, 19, 1574–82
   PubMedGoogle Scholar
• Ren B, McCrory MA, Pass C, et al. (2004). The virulence function of Streptococcus pneumoniae surface protein A involves inhibition of complement activation and impairment of complement receptor-mediated protection. J Immunol, 173, 7506–12
   PubMedGoogle Scholar
• Ren B, Szalai AJ, Hollingshead SK, Briles DE. (2003). Effects of PspA and antibodies to PspA on activation and deposition of complement on the Pneumococcal surface. Infect Immun, 72, 114–22
   Google Scholar
• Roche H, Hakansson A, Hollingshead SK, Briles DE. (2003). Regions of PspA/EF3296 best able to elicit protection against Streptococcus pneumoniae in a murine infection model. Infect Immun, 71, 1033–41
   Google Scholar
• Sampson JS, Furlow Z, Whitney AM, et al. (1997). Limited diversity of Streptococcus pneumonia psaA among pneumococcal vaccine serotypes. Infect Immun, 65, 1967–71
   PubMed Web of Science ®Google Scholar
• Shaper M, Hollingshead SK, Benjamin WH, Briles DE. (2004). PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin. Infect Immun, 72, 5031–40
   PubMed Web of Science ®Google Scholar
• Tai SS. (2006). Streptococcus pneumoniae protein vaccine candidates: Properties, activities and animal studies. Crit Rev Microbiol, 32, 139–53
   PubMed Web of Science ®Google Scholar
• Tart RC, McDaniel LS, Ralph BA, Briles DE. (1996). Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice. J infect Dis, 173, 380–6
   PubMedGoogle Scholar
• Tu AH, Fulgham RL, McCrory MA, et al. (1999). Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect Immun, 67, 4720–4
   PubMed Web of Science ®Google Scholar
• Walker CLF, Rudan I, Liu L, et al. (2013). Global burden of childhood pneumonia and diarrhoea. Lancet, 381, 1405–16
   PubMed Web of Science ®Google Scholar
• Wang S, Li Y, Shi H, et al. (2010). Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine. Infect Immun, 78, 3258–71
   PubMed Web of Science ®Google Scholar
• Whaley MJ, Sampson JS, Johnson SE, et al. (2010). Concomitant administration of recombinant PsaA and PCV7 reduces Streptococcus pneumoniae serotype 19A colonization in a murine model. Vaccine, 28, 3071–5
   PubMed Web of Science ®Google Scholar
• Zhang Z, Clarke TB, Weiser JN. (2009). Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J Clin Investig, 119, 1899–909
   PubMed Web of Science ®Google Scholar